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Abstract
Copy Number Variation (CNV) at the 1q21.1 locus is associated with a range of neurodevelopmental and psychiatric
disorders in humans, including abnormalities in head size and motor deficits. Yet, the functional consequences of these
CNVs (both deletion and duplication) on neuronal development remain unknown. To determine the impact of CNV at the
1q21.1 locus on neuronal development, we generated induced pluripotent stem cells from individuals harbouring 1q21.1
deletion or duplication and differentiated them into functional cortical neurons. We show that neurons with 1q21.1 deletion
or duplication display reciprocal phenotype with respect to proliferation, differentiation potential, neuronal maturation,
synaptic density and functional activity. Deletion of the 1q21.1 locus was also associated with an increased expression of
lower cortical layer markers. This difference was conserved in the mouse model of 1q21.1 deletion, which displayed altered
corticogenesis. Importantly, we show that neurons with 1q21.1 deletion and duplication are associated with differential
expression of calcium channels and demonstrate that physiological deficits in neurons with 1q21.1 deletion or duplication
can be pharmacologically modulated by targeting Ca2+ channel activity. These findings provide biological insight into the
neuropathological mechanism underlying 1q21.1 associated brain disorder and indicate a potential target for therapeutic
interventions.
Introduction
Investigating the biology of rare but relatively penetrant
copy number variants (CNVs), provides an opportunity to
understand the genetic basis of an increased susceptibility to
a range of neurodevelopmental and neuropsychiatric dis-
orders such as schizophrenia, autism, mental retardation and
epilepsy [1–7]. There are now several prominent examples
of pathogenic CNVs such as 1q21.1 deletions and dupli-
cations, 3q29 microduplications, 15q13.3 deletions,
16p11.2 deletions and duplications and 22q11.2 deletions
all of which are associated with increased risk for neuro-
developmental and neuropsychiatric disorders [8–10].
These CNVs are variable in size and can be either de novo
or familial [11, 12]. Furthermore, a recent study showed
that the brain is the tissue which is most intolerant to
CNV associated changes in gene dosage [13]. Therefore,
studying the impact of these CNVs on brain development
provides a window of opportunity to understand the cellular
mechanisms underlying increased risk for psychiatric
disorders.
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The 1q21.1 chromosomal locus (chr1: 146.57–147.39;
GRCh37/hg19) contains at least four low copy repeats
which render this region susceptible to non-allelic homo-
logous recombination leading to recurrent deletions and
duplications [14–16]. Although its prevalence worldwide is
not clear, data from UK Biobank has provided estimates of
a population frequency of 0.027% for the 1q21.1 deletion
and 0.044% for 1q21.1 duplication [17]. Two main classes
of the 1q21.1 CNVs has been described. The more common
Class I comprises the critical or distal region, whereas Class
II compromises of the Thrombocytopenia Absent Radius
(TAR) region in addition to the critical region [15, 18]. The
critical/distal region is ≈1.36Mb (from 145 to 146.35 Mb,
according to NCBI build 36) and contain at least 12 protein
coding genes, including PRKAB2, CHD1L, BCL9, ACP6,
GJA5, GJA8 and NOTCH2NL [9]. Phenotypes associated
with distal 1q21.1 deletion include developmental delay,
cognitive impairment, microcephaly, facial anomalies,
schizophrenia, attention deficit hyperactivity disorder,
emotional and behavioural problems. Whereas 1q21.1 distal
duplication has been associated with macrocephaly, devel-
opmental delay, autism spectrum disorder, cognitive
impairment, hypertelorism and congenital cardiac anoma-
lies [14, 15, 19–21]. Therefore, variation at this locus
represents a clear risk factor for a range of neuropsychiatric
disorders and need to be functionally characterised to
understand the contribution of this loci to neurodevelop-
mental deficits leading to associated developmental psy-
chiatric disorders. So far, the contribution of concomitantly
deleted or duplicated genes in this locus towards the
pathogenies of neuropsychiatric disorders is largely
unknown.
To understand the impact of the Class I 1q21.1 CNV
(from here referred to as 1q21.1 deletions or duplications)
on neuronal development, we established a cellular model
of by deriving human induced pluripotent stem cells
(iPSCs) from subjects carrying 1q21.1 deletion or duplica-
tion and differentiated them into cortical neurons. We
demonstrate that neural progenitor cells (NPCs) carrying
1q21.1 deletion or duplication are associated with early
neurodevelopmental phenotypes. Furthermore, these NPCs
after differentiation into neurons show dysregulated neu-
ronal development, associated with altered morphology and
synaptic density in comparison to controls. Moreover, these
neurons are associated with dysregulated cortical layer
identity. We validated aspects of these cellular phenotypes
in a 1q21.1 microdeletion mouse model and show that some
of these differences are conserved across species. Further-
more, we demonstrate that the presence of 1q21.1 CNVs
impact the physiological and electrical properties of neurons
as measured by calcium activity and multi-electrode arrays
(MEAs). Finally, using iPSC derived neurons with 1q21.1
CNVs as an in vitro pharmacological model, we show that
the aberrant physiological activity of these cells can be
modulated by targeting Ca2+ channels.
Methods
iPSC generation, characterisation and maintenance
Fibroblasts with subject carrying 1q21.1 deletion (n= 3) or
duplication (n= 2) were reprogrammed into induced plur-
ipotent stem cells (iPSCs) using the CytoTune™-IPS 2.0
Sendai reprogramming kit (Thermo-Fisher). Two estab-
lished iPSC lines were used as controls (IBJ4 see Plumbly
et al. [22] and HPSI1013i-wuye_2 purchased from HipSci).
Pluripotency was confirmed by immunofluorescence, qPCR
and trilineage differentiation (Supplementary Fig. 1–5).
iPSCs were grown on Geltrex™ coated plates in Essential
8™ Flex media. The cell lines were genotyped to identify
the location of 1q21.1 locus and to identify any pathoge-
netic CNVs. Further, the cell lines were regularly tested to
check any mycoplasma contamination.
Cortical neuronal differentiation
iPSCs were differentiated into cortical neurons using a
modified version of a previously described protocol [23].
Cells were maintained until 90–100% confluent at which
point the media was changed to N2B27- (2/3 DMEM/F12,
1/3 Neurobasal, N2 supplement, B27 supplement without
retinoic acid, penicillin, streptomycin, glutamine and β-
mercaptoethanol) supplemented with 250 nM LDN-
193189 (LDN) and 10 µM SB431542 (SB). For the sub-
sequent 10 days cells were maintained with both SB and
LDN and then they were passaged onto fibronectin. Cells
were maintained on fibronectin for 10 days in un-
supplemented N2B27- media with ½ media changes
every other day. Cells were then plated onto laminin and
poly-D-lysine coated plates and after 2 days the media
was replaced with N2B27+ (2/3 DMEM/F12, 1/3 Neu-
robasal, N2 supplement, B27 supplement, penicillin,
streptomycin, glutamine and β-mercaptoethanol) after a
further 2 days media was replaced with N2B27+ sup-
plemented with CultureOne™ supplement. After 2 days
media was replaced with fresh N2B27+ supplemented
with 5 µM DAPT and 1 µM PD0332991 (PD). Cells were
maintained with DAPT and PD for 4 days. Cells were then
dissociated using Accutase® Solution and were re-plated
on laminin and poly-D-lysine coated plates at a density of
200,000 cells/cm2. Cells were maintained in un-
supplemented N2B27+ for up to 20 days with ½ media
changes performed every other day. A minimum of three
independent neuronal differentiation of all iPSC lines
were done for the all the experiments reported.
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Calcium imaging
See Supplementary Methods for details
Multiple electrode arrays
See Supplementary Methods for details
Gene expression analysis, western blotting,
immunofluorescence and cell counting, histological
analysis of mice brains
Primers for all target genes and antibodies used are listed in
Supplemental Table 2 and 3 respectively. These procedures
are described in Supplementary Methods.
Subjects with &
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Statistical analyses
Data are expressed as mean ± SEM. All data are comprised
of a minimum of three separate differentiations (n) for each
cell line used in this study (2 control, 3 1q21.1 deletion and
2 1q21.1 duplication). All technical replicates were aver-
aged before statistical testing. Statistical analyses were
conducted in GraphPad Prism 6.01 (GraphPad Software).
Differences between conditions or groups were evaluated
using two-tailed unpaired Students T-Test or one/two-way
ANOVA. p values <0.05 were considered statistically
significant.
Results
Deletions and duplications of the 1q21.1 locus is
associated with altered neuronal development
We first assessed the effect of 1q21.1 deletion or duplication
on the expression of genes within the distal 1q21.1 region,
focusing on the expression of five key genes within this
locus. After 50 days of differentiation three of these critical
genes (BCL9, CDH1L and PRKAB2) had altered
expression in 1q21.1 deletion or duplication in comparison
to controls (Supplementary Fig. 6B). To determine if
deletion or duplication of the 1q21.1 locus altered neuro-
developmental trajectories we quantified the expression
level of: a neural stem cell marker (NESTIN [24]); a marker
of immature neurons Doublecortin (DCX [25]) and a mature
neuronal marker (MAP2 [26]) throughout the course of
neuronal differentiation and found that the expression level
in controls was in accordance with previously published
studies [27, 28]. NESTIN expression was significantly
higher in 1q21.1 duplication, but unchanged in the 1q21.1
deletion group after 20 days of differentiation (Fig. 1B).
Similarly, other NPC markers, PAX6 and PLZF, was also
elevated in duplications, but no change was seen for ZO-1
(Supplementary Fig. 7B). However, at day 20 NESTIN+
cells were similar across group (Fig. 1M). Further, we
observed a small, but significant decrease of Ki67+ cells in
1q21.1 deletion culture at day 20 and a substantial decrease
in Ki67 mRNA was seen at day 30 (Fig. 1F–I, Supple-
mentary Fig. 7D). 1q21.1 duplication culture exhibit ele-
vated Ki67 mRNA expression at day 30 (Supplementary
Fig. 7D).
DCX expression in the 1q21.1 duplication group showed
an increased expression at day 40 and 50. In contrast,
1q21.1 deletion cell exhibited a more complex pattern with
decreased expression at day 30, but increased expression at
day 40. However, the levels were comparable to controls at
day 50 (Fig. 1C). Similarly, TUJ1 expression was higher in
duplication and of comparable level between deletion and
controls at day 50 (Supplementary Fig. 7K–N). MAP2
expression both at protein and mRNA level were sig-
nificantly reduced throughout neuronal differentiation in
1q21.1 duplication. This was further accompanied by a
reduced number of MAP2+ cells at day 30 (Fig. 1D, E, Q).
The 1q21.1 deletion group demonstrated an increased
MAP2 expression and an increase in MAP2+ cells
(Fig. 1D, Q). Although we note an increase in MAP2 pro-
tein levels at day 50, it did not reach significance (Fig. 1E).
Neuronal cell morphologies were examined at day 30 of
neuronal differentiation when neuronal morphology first
emerge [23] (Supplementary Fig. 8). Neurons with 1q21.1
deletion had smaller soma, whereas 1q21.1 duplication had
an increased soma size. These results indicate that 1q21.1
CNV alter neuronal differentiation, and differences begin to
emerge at the Neural Progenitor Cell (NPC) stage. These
results show that a complex set of gene expression and
protein changes occur during neurodevelopment of 1q21.1
CNV patient cells, which are unlikely to arise from a simple
acceleration or retardation of the neuronal differentiation
programme. However, they do suggest that the 1q21.1
duplication may delay the transition from NPC to neurons,
whereas a 1q21.1 deletion suppresses proliferation and
promotes neuronal production.
Fig. 1 Cortical neurons with 1q21.1 deletion and duplications are
associated with aberrant maturation. AWorkflow for the generation
of stable iPSC lines from human fibroblast carrying 1q21.1 deletions
and duplication and the subsequent conversion of iPSC into functional
neurons. B–D Gene expression analysis for the expression of NESTIN,
DCX and MAP2 from day 20 to day 50 of neuronal differentiation in
control, 1q21.1 deletion and 1q21.1 duplication neuronal culture.
NESTIN, genotype (F2,72= 7.94; P < 0.001; n ≥ 3/group), time (F3,72
= 193; P < 0.0001; n ≥ 3/group); DCX, genotype (F2,72= 7.561; P <
0.0001; n ≥ 3/group), time (F3,72= 120.4; P < 0.0001; n ≥ 3/group)
interaction between genotype and time (F6,72= 20.88, P < 0.0001, n ≥
3/group); MAP2, genotype (F2,72= 28.17; P < 0.0001; n ≥ 3/group),
time (F3,72= 53.13; P < 0.0001; n ≥ 3/group). Data sets were analysed
by two-way ANOVA with post hoc comparisons using Dunnett’s
multiple comparisons test comparing to control samples. Stars above
points represent significance following Dunnett-corrected post hoc
tests. E Representative western blot protein bands and quantitative
analysis for MAP2 expression normalised to GAPDH (n ≥ 3). F–H
Example images of KI67+ staining at day 20 of neuronal differ-
entiation in control, 1q21.1 deletion and 1q21.1 duplication cell lines.
I Quantification of the percentage of DAPI+ nuclei which colocalized
with KI67 positivity in day 20 neuronal cultures (n ≥ 3). J–L Repre-
sentative images of NESTIN+ cells at day 20 of neuronal differ-
entiation in control, 1q21.1 deletion and 1q21.1 duplication cell lines.
M Quantification of the area which staining positive for NESTIN
normalised to the number of cell present in the field (n ≥ 3). N–P
Representative images of MAP2 positive immature neurons after
30 days of differentiation from a control, 1q21.1 deletion and 1q21.1
duplication cell line. Q Quantification of the percentage of DAPI+
nuclei that are colocalized with MAP2 positivity in immature neuronal
cultures after 30 days of differentiation (n ≥ 3). Unless otherwise
specified data were analysed using Students T-Tests. All data are
presented as means ± SEM *P < 0.05; **P < 0.01; ***P < 0.001
****P < 0.0001 vs. control. Scale bar= 100 µm.
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Neurons with 1q21.1CNVs exhibit alterations in the
cortical neuronal identity
Alternation in corticogenesis has been linked to many
developmental psychiatric disorders [29], risk for which
has been associated with CNVs at 1q21.1 locus.
We therefore looked at the formation of the early
born deep layer neurons specifically examining the
expression of CTIP2 and TBR1. The neurons carrying
1q21.1 deletion were associated with an increased
expression of TBR1 and CTIP2 both at transcript and
protein level following 50 days of differentiation. These
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results were confirmed using immunocytochemistry and
indicate an increase in the number of CTIP2+ cells in
1q21.1 deletion. Conversely, 1q21.1 duplication was
associated with a transient increase of TBR1 expression at
day 30 of differentiation and no significant change in
CTIP2 expression. Furthermore, at the protein and cel-
lular level, the expression of TBR1 and CTIP2 in 1q21.1
duplication cultures were comparable to controls
(Fig. 2A–C, G–I).
To examine the potential effects that the changes seen in
differentiating cells may have on brain organisation, we
analysed 1-month old brains of a mouse model with a
1q21.1 microdeletion [30]. This analysis demonstrated that
there was a significantly higher proportion of TBR1 cells in
brains of the 1q21.1 mouse model in comparison to control
littermates (Fig. 2M). These data suggest that 1q21.1 dele-
tion result in altered cortical patterning due to an increase in
the production of lower layer cortical neurons.
Human neurons with 1q21.1 deletion or duplication
are associated with defects in synaptogenesis
Considering the altered differentiation potential associated
with 1q21.1 deletion/duplication, we investigated the
impact of the 1q21.1 CNV on synaptogenesis in our patient
iPSC-derived neurons. The postsynaptic marker, PSD-95
showed a reciprocal pattern for both gene expression and
protein analysis with an increased expression in 1q21.1
deletion and a decrease in 1q21.1 duplication neuronal cell
(Fig. 3A, B; Supplementary Fig. 9). The presynaptic marker
(synaptophysin; SYN) showed an increased gene expres-
sion and number of SYN+ puncta in the 1q21.1 deletion.
On the other hand, duplication of the 1q21.1 locus was
associated with a decrease of SYN+ puncta and a decrease
of SYN protein level (Fig. 3C) when normalised to
MAP2 (eliminating differences in morphology)
(Fig. 3C–E). These results demonstrate that both 1q21.1
deletion and duplication are associated with defects in
synapse development. It has previously shown that the
presence of astrocytes influences the synapse formation in
iPSC derived neurons [31]. Hence, we quantified the level
of GFAP and S100β expression at day 40 and day 50, we
found that level of GFAP and S100β was significantly
minimal to the MAP2 expression (Supplementary Fig. 7I, J)
and across groups.
Spontaneous calcium activity reveals physiological
deficits in neurons associated with 1q.21 deletion or
duplications
To begin to understand the effects of 1q21.1 CNV on the
physiology of neurons we assessed the cytosolic dynamics
of calcium using a calcium-sensitive dye. A similar pro-
portion of cells showed spontaneous calcium activity in the
control and 1q21.1 deletion cultures (Fig. 4A). However,
there were significantly fewer active neuronal cells in
1q21.1 duplication cultures compared to the controls
(Fig. 4A). Quantifying the rate of spontaneous calcium
activity showed a significant increase in the rate of calcium
events in neurons with 1q21.1 deletion (Fig. 4B). On the
other hand, after excluding the inactive cells the rate of
calcium events in 1q21.1 duplication cultures was similar to
the controls (Fig. 4B). Finally, the amplitude of calcium
signals was comparable across the groups with no sig-
nificant differences between control, deletion and duplica-
tion neurons (Fig. 4C).
We then investigated the effect of the NMDA receptor
antagonist AP5 (D-2-amino-5-phosphonopentanoate) and
the AMPA receptor antagonist CNQX (6-Cyano-7-nitro-
quinoxaline-2,3-dione) in modulating the calcium signal in
the neurons (Supplementary Fig. 10A). The addition of AP5
or CNQX resulted in a decrease in the percentage of active
Fig. 2 Deletion or duplication of the 1q21.1 locus is associated with
aberrant cortical neuron differentiation similar to deficits found in
the 1q21.1 microdeletion mouse model. A Gene expression of cor-
tical deep layer marker TBR1 through the course of the neuronal
differentiations (from day 20 to day 50). Both genotype (F2,84= 57.55;
P < 0.0001; n ≥ 3/group) and time (F3,84= 365.8; P < 0.0001; n ≥ 3/
group) had significant effects on TBR1 expression. B Representative
western blot protein bands and quantitative analysis of TBR1
expression normalised to GAPDH (n ≥ 3). C Quantification of the
percentage of MAP2 positive cells which co-localised with TBR1 (n ≥
3). D-F Representative images of MAP2 and TBR1 colocalization
from a control, deletion and duplication cell line. G The expression of
CTIP2 through the course of neuronal differentiation (from day 20 to
day 50). Both genotype (F2,84= 199.7; P < 0.0001; n ≥ 3/group) and
time (F3,84= 133.2; P < 0.0001; n ≥ 3/group) had significant effects on
CTIP2 expression. H Representative western blot protein bands and
quantitative analysis for CTIP2 expression normalised to GAPDH (n ≥
3). I Quantification of the percentage of MAP2 positive cells which co-
express CTIP2 (n ≥ 3). J-L Representative images MAP2 and CTIP2
colocalization from a control, deletion and duplication cell line. Scale
bar= 100 µm. Data sets are expressed as mean of at least three inde-
pendent experiments and were analysed by Students T-Test or two-
way ANOVA with post hoc comparisons using Dunnett’s multiple
comparisons test comparing to control samples. Where appropriate
stars above points represent Dunnett-corrected post hoc tests.
M Quantification of TBR1+ nuclei in the somatosensory cortex of
adult mice modelling 1q21.1 deletion and wild type liter matched
controls (WT) given as a percentage of nuclei in a 300 µm section of
cortex. N Quantification of CTIP2+ nuclei in the somatosensory
cortex of adult mice modelling 1q21.1 microdeletion and liter matched
controls given as a percentage of nuclei in a 300 µm section of cortex.
Data were analysed using Student’s T-tests with six animals per group
and n ≥ 3 for each animal. All data are presented as means ± SEM *P <
0.05; **P < 0.01; ***P < 0.001 ****P < 0.0001 vs. control.
O Representative images of a coronal brain section of wild type (WT)
and 1q21.1 microdeletion model (1q21.1) showing the expression of
Tbr1+ cells in the somatosensory cortex of 1-month old adult mice.
P Representative images of a coronal brain section of wild type (WT)
and 1q21.1 microdeletion model (1q21.1) showing the expression of
Ctip2+ cells in the somatosensory cortex of 1-month old adult mice.
Scale Bar= 100 µm.
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neurons in both the control and 1q21.1 deletion neuronal
cultures. Whereas only inhibition of AMPA receptors
showed a minor but significant decrease in the percentage of
active neurons in 1q21.1 duplication cultures, indicating
that 1q21.1 deletion neurons form connections similar to
controls but the calcium activity of 1q21.1 duplication
neurons could be associated with complex intricate
pathways.
Neurons with 1q21.1 deletion or duplication display
aberrant neural network activity
The results above indicate that 1q21.1 deletion develops
rapidly, expressing neurodevelopmental genes earlier than
control cells, exhibiting increased synaptogenesis and
increased numbers of calcium events. In contrast, 1q21.1
duplication cells showed slow or aberrant neurodevelop-
ment, formed fewer synapses and only ≈50% of neurons
had active calcium signalling. We therefore examined the
effect of the CNVs on neuronal network activity by use of
Multi-Electrode Array (MEA) recordings [32]. Such net-
works are dependent on formation of functional synapses
and are good indicators of neuronal deficits arising from
aberrant neurodevelopment.
Analysis of neuronal activity over a period of 50 days post
plating onto the MEA showed that neurons with 1q21.1
deletion exhibited significantly higher spike rates and fre-
quency of bursting compared to control neurons, particularly
after D70 (Fig. 4F, G). In contrast, 1q21.1 duplication cells
show no significant increases in either spike rate or burst rate
during development. These data are consistent with the altered
neuronal activity observed by calcium imaging. Later devel-
opment time points on our MEA correspond to the emergence
of large, synaptically connected neuronal networks, which
burst fire in synchrony. 1q21.1 deletion patient cells exhibited
synchronised bursting earlier in neuronal development (D70)
than control cells (D100). Interestingly, the ultimate outcome
for the neuronal network is not an increase in frequency of
SBs between 1q21.1 deletion cultures and control cultures
(Fig. 4M), but an increase SB duration (Fig. 4N), This
aberrant network activity was inhibited by the NMDA inhi-
bitor AP5 and the AMPA inhibitor NBQX (2,3-dihydroxy-6-
nitro-7-sulfamoyl-benzo[f]quinoxaline) (Supplementary
Fig. 10B–D), indicative of a glutamate transmitter dependent
neuronal network. This is consistent with the higher synapse
number seen in 1q21.1 deletion patient cells. In contrast,










































































































































































Fig. 3 Neurons with 1q21.1 deletion and duplication are associated
with synaptic defects. A The expression of PSD95 mRNA at day 50
of neuronal differentiation (n ≥ 3). B Representative western blot
protein bands and quantitative analysis for Synaptophysin expression
normalised to both GAPDH and MAP2 (n ≥ 3). C The expression of
Synaptophysin mRNA at day 50 of neuronal differentiation (n ≥ 3). D
Representative western blot protein bands and quantitative analysis for
Synaptophysin expression normalized to both GAPDH and MAP2
(n ≥ 3). E Quantification of the number of Synaptophysin positive
puncta normalised to the dendritic area stained positive for MAP2 (n ≥
3). F Representative images of Synaptophysin (SYN, red) positive
puncta in MAP2 (green) positive control, deletion and duplication
neurons. Scale bar= 50 µm. Data were analysed using Students T-
Tests and all data are presented as means ± SEM **P < 0.01; ***P <
0.001 vs. control.
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Aberrant physiological activity of neurons with
1q21.1 deletion or duplications can be rescued by
modulation of Ca2+ activity
To determine a putative drug target to modulate the phy-
siological deficits associated with 1q21.1 deletion and
duplication, we first assessed the effect of 1q21.1 mutations
on the expression of neuronal ion channels. Duplication of
the 1q21.1 locus was associated with a decrease in the
expression of most ion channels (Fig. 5A). On the other
hand, subunits of the AMPA and NMDA receptors
(GLUA1 and GRIN1), and voltage-gated calcium channels
CACNA1B and CACNA1E showed increased expression
in 1q21.1 deletion neurons relative to control (Fig. 5A,
Supplementary Fig. 11). To investigate whether a suppres-
sion of calcium signalling could reverse the increased Ca2+
spiking seen in 1q21.1 deletion neurons, we added a
voltage-gated calcium channel blocker, verapamil [33, 34],
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to neuronal cultures. Verapamil caused a significant
reduction in the rate of Ca2+ events in 1q21.1 deletion
neurons (Fig. 5C). However, there was an increased rate of
Ca2+ events in control neurons. These results suggest that
the blockage of calcium channels can dampen the increased
rate of calcium events in 1q21.1 deletion neurons.
To induce Ca2+ activity in the population of inactive
cells in 1q21.1 duplication cultures, they were treated with
roscovitine, which has shown to prolong the deactivation
time of neuronal calcium channels [35, 36]. Addition of
roscovitine significantly increased the number of calcium
events in both control and 1q21.1 duplication neuronal
culture (Fig. 5F). However, addition of roscovitine did not
increase the proportion of spontaneously active cells in
1q21.1 duplication cultures (Fig. 5E). These results suggest
that the higher and lower Ca2+ activity in 1q21.1 deletions
and duplications can be modulated by targeting L type
calcium channel antagonist and agonist.
Discussion
One of the key findings of the study is a mirrored phenotype
with respect to neuronal differentiation. Deletion of the
1q21.1 locus was associated with accelerated neuronal
differentiation whereas duplication of the 1q21.1 locus had
negative effects on differentiation potential. These opposing
phenotypes represent a possible explanation for the micro
and macrocephaly associated with CNVs at the 1q21.1
locus. In 1q21.1 deletion subjects the accelerated differ-
entiation may result in premature loss of proliferative pre-
cursors or in premature death of new-born neurons. In
1q21.1 duplication subjects the retention of proliferative
progenitors and resistance to produce mature neurons is
likely result in an increase in overall cell number. However,
additional work is needed in additional cellular models
together with mice model to validate these explanations.
The distal 1q21.1 region consist of at least 12 protein
coding genes with the recent additions of NOTCH2NLA,
NOTCH2NLB and NOTCH2NLC being of particular
interest [37]. A recent study investigated the effect of
NOTCH2NLB on brain development demonstrated that
deletion of this gene leads to premature neuronal matura-
tion, whereas ectopic expression lead to a delay in the dif-
ferentiation of radial glial cells [38]. These results are
consistent with the cellular phenotypes presented in this
study and provide some evidence for the underlying
mechanisms involved. Given the neurodevelopment phe-
notype that is associated 1q21.1 CNV in our cultures it is
possible that these can be attributed to dosage variation of
the NOTCH2NL gene. However, the contribution of other
genes within the distal 1q21.1 locus has yet to be explored;
more genetic manipulation studies are needed to elucidate
the contribution of each gene towards the pathology asso-
ciated with 1q21.1 CNVs and it is likely that dosage level of
the genes are associated stages of neuronal differentiation.
Importantly, at a functional level deletion of the 1q21.1
distal locus was associated with increase neuronal activity
and deficits in neuronal network functionality (specifically
in the duration of synchronised bursts). On the other hand,
duplication of the 1q21.1 locus was associated with
decreased neuronal activity and an inability to form neu-
ronal networks. These phenotypes are in part likely a result
of the altered synapse production associated with CNVs at
the 1q21.1 locus. However, the cause of this synaptic dis-
parity is not clear. Our result demonstrate that altered
synaptogenesis is mediated by altered expression of syna-
pasin and PSD95. Future studies looking into expression
analysis of these neurons will help in identifying other
associated factors and in elucidating underlying common
pathways (altered transcription/altered mRNA degradation
and translation), associated with synaptogenesis. Several
cellular studies looking at cellular phenotypes of other
CNVs such as 2p16.3/NRXN1, 15q13.3, 16p11.2, 22q11.21
have also shown synaptic dysfunction [39–41]. Therefore,
cellular dysfunction associated with CNVs (linked to psy-
chiatric disorders) is likely to converge on deficiencies in
synaptic machinery.
Fig. 4 Neurons with 1q21.1 deletion and duplication display
altered calcium transient activity. A Quantification of neuronal soma
which show at least one characteristically neuronal calcium event (n ≥
3). B Number of characteristically neuronal calcium events recorded
per minute per active neurons across different groups (n ≥ 3). C
Amplitude of calcium signals recorded from active neuronal cells
across different groups. D Representative traces of calcium events as
measured by changes in fluorescence from a control, deletion and
duplication cell line (n ≥ 3). E Representative raster plot of neuronal
activity exhibited by control, deletion and duplication-derived neurons
at early (D70) and late (D100) neurodevelopmental stages. Red boxes
indicate periods of synchronised neuronal bursts. F The average
number of spikes recorded per electrode across the 50 days cells were
maintained on MEAs. Both genotype (F2,76= 18.06; P < 0.0001; n ≥ 3/
group) and time (F4,76= 3.536; P < 0.05; n ≥ 3/group) had significant
effects on the average number of spikes per electrode. G The average
number bursts (defined as when more than three electrodes were active
in the same 200 ms time frame) per culture across the 50 days cells
were maintained on MEAs. Only genotype (F2,61= 8.637; P < 0.001;
n ≥ 3/group) had a statically significant effects on the number of bursts
per culture per recording. H, I, J Examples of array-wide spike
detection rate (ASDR) plots, which form the basis of synchronised
burst (SB) analyses. K, L Representative raster plots showing the
length and interval between SBs (indicated by the red boxes) of control
networks as compared to those of 1q21.1 deletion.M Quantification of
network bursting interval in control and 1q21.1 deletion neurons (n ≥
3). N Quantification of network burst duration in control and 1q21.1
deletion neurons (n ≥ 3). Data sets were analysed by Students T-Test or
two-way ANOVA with post hoc comparisons using Dunnett’s multi-
ple comparisons test comparing to control samples. Stars above points
represent Dunnett-corrected post hoc tests. All data are presented as
means ± SEM *P < 0.05; **P < 0.01; ***P < 0.001 ****P < 0.0001
vs. control.
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Our results demonstrate that addition of verapamil (a
calcium channel antagonist) could reduce the rate of cal-
cium transients in 1q21.1 deletion neurons. While some
studies have questioned the specificity of verapamil
[42, 43], our results suggests that the changes in calcium
dynamics seen in 1q21.1 deletion neurons can be modulated
by altering the activity of voltage-gated calcium channels.
The contribution and involvement of other calcium chan-
nels however cannot be ruled out. While verapamil has been
used as a treatment for bipolar disorder, albeit with limited
sucess [44], it has been shown to improve scopolamine-











































































































































































Fig. 5 Pharmacological modulation of L-type calcium channel
rescues abnormal calcium activity in neurons with 1q21.1 dele-
tions and duplications. A Expression of key neuronal channels in
1q21.1 deletion and duplication neurons following 50 days of neuronal
differentiation. The values are presented as fold change compared to
expression in controls. Data were analysed using multiple T tests (n ≥
3) and significance is based on Holm–Sidak corrected P values. All
data are presented as means ± SEM *P < 0.05; **P < 0.01; ***P <
0.001 ****P < 0.0001 vs. control. B Quantification of neuronal soma
which show at least one characteristically neuronal calcium event in
day 50 control and 1q21.1 deletion culture treated for 10 days with
vehicle (DMSO) or verapamil (n ≥ 3/group). C Number of neuronal
calcium events recorded per minute in day 50 control and 1q21.1
deletion cultures treated for 10 days with vehicle (DMSO) or ver-
apamil. Both genotype (F1,28= 71.64; P < 0.0001; n ≥ 3/group) and the
addition of verapamil (F2,28= 79.56; P < 0.0001; n ≥ 3/group) had
significant effects on the average rate of calcium events. Furthermore,
there was a significant interaction between the effect of genotype and
drug (F2,28= 162.4; P < 0.0001; n ≥ 3/group) on the rate of calcium
events. D Example traces of single neurons from both control and
1q21.1 deletion neurons treated with vehicle or verapamil. E Quanti-
fication of soma which show at least one characteristically neuronal
calcium event in day 50 control and 1q21.1 deletion cultures treated
for 10 days with vehicle (DMSO) or roscovitine. Only genotype had a
significant effect on the percentage of active cells (F1,22= 463.9; P <
0.0001; n ≥ 3/group). F Number of characteristically neuronal calcium
events recorded per minute in day 50 control and 1q21.1 duplication
cultures treated for 10 days with vehicle (DMSO) or roscovitine. Both
genotype (F1,22= 38.1; P < 0.0001; n ≥ 3/group) and the addition of
roscovitine (F2,22= 63.87; P < 0.0001; n ≥ 3/group) had significant
effects on the average rate of calcium events. Furthermore, there was a
significant interaction between the effect of genotype and drug
(F2,22= 16.06; P < 0.0001; n ≥ 3/group) on the rate of calcium events.
G Representative traces of single neurons from both control and
1q21.1 duplication cultures treated with vehicle or roscovitine. Data
sets were analysed by two-way ANOVA with post hoc comparisons
using Dunnett’s multiple comparisons test comparing to control
vehicle treated samples. Stars above points represent Dunnett-
corrected post hoc tests. All data are presented as means ± SEM;
***P < 0.001 ****P < 0.0001 vs. vehicle treated control.
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Roscovitine was used in an attempt to induce calcium
activity in inactive 1q21.1 duplication cells by inhibiting
cell cycle progression and modulating calcium channel
activity [35, 47]. The addition of roscovitine was able to
increase calcium activity in 1q21.1 duplication neurons
consistent with previous studies [48]. However, roscovitine
failed to increase the proportion of active neurons in either
the control of 1q21.1 duplication group.
The present study focussed largely on identifying broad
classes of neuronal dysfunction and therefore further work
is necessary to elucidate the precise molecular mechanisms
which underly the cellular phenotypes identified in this
study. Critically future work using global transcriptomic
analysis may help in identifying the precise genetic
mechanisms underlying the dysfunctions identified in
this study.
Acknowledgements We thank Craig Joyce and Olena Peter for their
help in reprogramming cells and Dr. Faraz Mahmood Ali of the Dept.
of Dermatology, University Hospital Wales for the skin biopsies.
Funding This work was supported by CMU fellowship to YAS. GC,
AJH and JH are supported by TWF Changing Minds Programme. JH,
AJH, DEJL and MO is supported by Welcome (DEFINE Strategic
Award 100202/Z/12/Z). JH is also supported by Hodge Foundation
(Centre Grant) and MRC grants (MR/ L010305/1, G0800509, MR/
NO22572/1 and MR/L011166/1). MBMvdB is supported by MRC
grants (MR/N022572/1 and MR/L011166/1). The work was also
support from core facilities of the Neuroscience and Mental Health
Research Institute, Cardiff University, UK and the National Centre for
Mental Health was supported with funds from Health and Care
Research Wales.
Author contributions Conceptualisation: YAS; Planning, design and
instigation: GC, YAS; Investigation, analysis and methodology: GC,
MA, SL, TS, YAS; Resources including participant testing: JH, DEJL,
MvdB, MO, MZ; Figures and initial writing; GC, YAS; Writing and
editing of manuscript; GC, JH, AJH, YAS. All authors have read and
reviewed the manuscript.
Compliance with ethical standards
Conflict of interest The authors declare no competing interests.
Ethics statement Generation and use of human iPSC were approved
by the Cardiff University and HSE (GMO130/19.3). Clinical and
psychometric testing (supplementary table 1) of participants and skin
biopsies was approved by the Regional Ethics Committee of the
National Health Service (study 14/WA/0035).
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Cooper GM, Coe BP, Girirajan S, Rosenfeld JA, Vu TH, Baker C,
et al. A copy number variation morbidity map of developmental
delay. Nat Genet. 2011;43:838–46.
2. Gilissen C, Hehir-Kwa JY, Thung DT, van de Vorst M, van Bon
BW, Willemsen MH, et al. Genome sequencing identifies major
causes of severe intellectual disability. Nature. 2014;511:344–7.
3. Krumm N, Turner TN, Baker C, Vives L, Mohajeri K, With-
erspoon K, et al. Excess of rare, inherited truncating mutations in
autism. Nat Genet. 2015;47:582–8.
4. Marshall CR, Howrigan DP, Merico D, Thiruvahindrapuram B,
Wu W, Greer DS, et al. Contribution of copy number variants to
schizophrenia from a genome-wide study of 41,321 subjects. Nat
Genet. 2017;49:27–35.
5. Williams NM, Zaharieva I, Martin A, Langley K, Mantripragada
K, Fossdal R, et al. Rare chromosomal deletions and duplications
in attention-deficit hyperactivity disorder: a genome-wide analy-
sis. Lancet. 2010;376:1401–8.
6. Chawner S, Owen MJ, Holmans P, Raymond FL, Skuse D, Hall J,
et al. Genotype-phenotype associations in children with copy
number variants associated with high neuropsychiatric risk in the
UK (IMAGINE-ID): a case-control cohort study. Lancet Psy-
chiatry. 2019;6:493–505.
7. Eaton CB, Thomas RH, Hamandi K, Payne GC, Kerr MP, Linden
DEJ, et al. Epilepsy and seizures in young people with 22q11.2
deletion syndrome: Prevalence and links with other neurodeve-
lopmental disorders. Epilepsia. 2019;60:818–29.
8. Kirov G. CNVs in neuropsychiatric disorders. Hum Mol Genet.
2015;24:R45–49.
9. Torres F, Barbosa M, Maciel P. Recurrent copy number variations
as risk factors for neurodevelopmental disorders: critical overview
and analysis of clinical implications. J Med Genet. 2016;53:73–90.
10. Niarchou M, Chawner S, Doherty JL, Maillard AM, Jacquemont
S, Chung WK, et al. Psychiatric disorders in children with
16p11.2 deletion and duplication. Transl Psychiatry. 2019;9:8.
11. Woodbury-Smith M, Paterson AD, Thiruvahindrapduram B,
Lionel AC, Marshall CR, Merico D, et al. Using extended pedi-
grees to identify novel autism spectrum disorder (ASD) candidate
genes. Hum Genet. 2015;134:191–201.
12. Neale BM, Kou Y, Liu L, Ma’ayan A, Samocha KE, Sabo A,
et al. Patterns and rates of exonic de novo mutations in autism
spectrum disorders. Nature. 2012;485:242–5.
13. Ruderfer DM, Hamamsy T, Lek M, Karczewski KJ, Kavanagh D,
Samocha KE, et al. Patterns of genic intolerance of rare copy
number variation in 59,898 human exomes. Nat Genet.
2016;48:1107–11.
14. Mefford HC, Sharp AJ, Baker C, Itsara A, Jiang Z, Buysse K,
et al. Recurrent rearrangements of chromosome 1q21.1 and vari-
able pediatric phenotypes. N. Engl J Med. 2008;359:1685–99.
15. Brunetti-Pierri N, Berg JS, Scaglia F, Belmont J, Bacino CA,
Sahoo T, et al. Recurrent reciprocal 1q21.1 deletions and dupli-
cations associated with microcephaly or macrocephaly and
developmental and behavioral abnormalities. Nat Genet.
2008;40:1466–71.
16. Sharp AJ, Locke DP, McGrath SD, Cheng Z, Bailey JA, Vallente
RU, et al. Segmental duplications and copy-number variation in
the human genome. Am J Hum Genet. 2005;77:78–88.
Using induced pluripotent stem cells to investigate human neuronal phenotypes in 1q21.1 deletion and. . .
17. Owen D, Bracher-Smith M, Kendall KM, Rees E, Einon M,
Escott-Price V, et al. Effects of pathogenic CNVs on physical
traits in participants of the UK Biobank. BMC Genomics.
2018;19:867.
18. Dolcetti A, Silversides CK, Marshall CR, Lionel AC, Stavro-
poulos DJ, Scherer SW, et al. 1q21.1 Microduplication expression
in adults. Genet Med. 2013;15:282–9.
19. Buse M, Cuttaia HC, Palazzo D, Mazara MV, Lauricella SA,
Malacarne M, et al. Expanding the phenotype of reciprocal 1q21.1
deletions and duplications: a case series. Ital J Pediatr.
2017;43:61.
20. Rosenfeld JA, Traylor RN, Schaefer GB, McPherson EW, Ballif
BC, Klopocki E, et al. Proximal microdeletions and micro-
duplications of 1q21.1 contribute to variable abnormal pheno-
types. Eur J Hum Genet. 2012;20:754–61.
21. Cunningham AC, Hall J, Einfeld S, Owen MJ, consortium I-I, van
den Bree MBM. Assessment of emotions and behaviour by the
Developmental Behaviour Checklist in young people with neu-





22. Plumbly W, Brandon N, Deeb TZ, Hall J, Harwood AJ. L-type
voltage-gated calcium channel regulation of in vitro human cor-
tical neuronal networks. Sci Rep. 2019;9:13810.
23. Chambers SM, Qi Y, Mica Y, Lee G, Zhang XJ, Niu L, et al.
Combined small-molecule inhibition accelerates developmental
timing and converts human pluripotent stem cells into nociceptors.
Nat Biotechnol. 2012;30:715–20.
24. Lendahl U, Zimmerman LB, McKay RD. CNS stem cells
express a new class of intermediate filament protein. Cell.
1990;60:585–95.
25. Gleeson JG, Lin PT, Flanagan LA, Walsh CA. Doublecortin is a
microtubule-associated protein and is expressed widely by
migrating neurons. Neuron. 1999;23:257–71.
26. Harada A, Teng J, Takei Y, Oguchi K, Hirokawa N. MAP2 is
required for dendrite elongation, PKA anchoring in dendrites, and
proper PKA signal transduction. J Cell Biol. 2002;158:541–9.
27. Pasca SP, Portmann T, Voineagu I, Yazawa M, Shcheglovitov A,
Pasca AM, et al. Using iPSC-derived neurons to uncover cellular
phenotypes associated with Timothy syndrome. Nat Med.
2011;17:1657–62.
28. Meyer K, Feldman HM, Lu T, Drake D, Lim ET, Ling KH, et al.
REST and neural gene network dysregulation in iPSC models of
Alzheimer’s disease. Cell Rep. 2019;26:1112–27. e1119
29. Rubenstein JL. Annual research review: development of the cer-
ebral cortex: implications for neurodevelopmental disorders. J
Child Psychol Psychiatry. 2011;52:339–55.
30. Nielsen J, Fejgin K, Sotty F, Nielsen V, Mork A, Christoffersen
CT, et al. A mouse model of the schizophrenia-associated 1q21.1
microdeletion syndrome exhibits altered mesolimbic dopamine
transmission. Transl Psychiatry. 2017;7:1261.
31. Klapper SD, Garg P, Dagar S, Lenk K, Gottmann K, Nieweg K.
Astrocyte lineage cells are essential for functional neuronal dif-
ferentiation and synapse maturation in human iPSC-derived neural
networks. Glia. 2019;67:1893–909.
32. Odawara A, Katoh H, Matsuda N, Suzuki I. Physiological
maturation and drug responses of human induced pluripotent stem
cell-derived cortical neuronal networks in long-term culture. Sci
Rep. 2016;6:26181.
33. Dobrev D, Milde AS, Andreas K, Ravens U. The effects of ver-
apamil and diltiazem on N-, P- and Q-type calcium channels
mediating dopamine release in rat striatum. Br J Pharm.
1999;127:576–82.
34. MacDonald JF, Schneiderman JH. Actions of verapamil on the
excitability of cultured neurones. Can J Physiol Pharm.
1983;61:1467–72.
35. Buraei Z, Anghelescu M, Elmslie KS. Slowed N-type calcium
channel (CaV2.2) deactivation by the cyclin-dependent kinase
inhibitor roscovitine. Biophys J. 2005;89:1681–91.
36. Tarr TB, Malick W, Liang M, Valdomir G, Frasso M, Lacomis D,
et al. Evaluation of a novel calcium channel agonist for ther-
apeutic potential in Lambert-Eaton myasthenic syndrome. J
Neurosci. 2013;33:10559–67.
37. Steinberg KM, Schneider VA, Graves-Lindsay TA, Fulton RS,
Agarwala R, Huddleston J, et al. Single haplotype assembly of the
human genome from a hydatidiform mole. Genome Res.
2014;24:2066–76.
38. Fiddes IT, Lodewijk GA, Mooring M, Bosworth CM, Ewing AD,
Mantalas GL, et al. Human-specific NOTCH2NL genes affect
notch signaling and cortical neurogenesis. Cell.
2018;173:1356–69. e1322
39. Uddin M, Unda BK, Kwan V, Holzapfel NT, White SH, Chalil L,
et al. OTUD7A regulates neurodevelopmental phenotypes in the
15q13.3 microdeletion syndrome. Am J Hum Genet.
2018;102:278–95.
40. Deshpande A, Yadav S, Dao DQ, Wu ZY, Hokanson KC, Cahill
MK, et al. Cellular phenotypes in human iPSC-derived neurons
from a genetic model of autism spectrum disorder. Cell Rep.
2017;21:2678–87.
41. Gokhale A, Hartwig C, Freeman AAH, Bassell JL, Zlatic SA, Sapp
Savas C, et al. Systems analysis of the 22q11.2 microdeletion syn-
drome converges on a mitochondrial interactome necessary for
synapse function and behavior. J Neurosci. 2019;39:3561–81.
42. Cai D, Mulle JG, Yue DT. Inhibition of recombinant Ca2+
channels by benzothiazepines and phenylalkylamines: class-
specific pharmacology and underlying molecular determinants.
Mol Pharm. 1997;51:872–81.
43. Tarabova B, Lacinova L, Engel J. Effects of phenylalkylamines
and benzothiazepines on Ca(v)1.3-mediated Ca2+ currents in
neonatal mouse inner hair cells. Eur J Pharm. 2007;573:39–48.
44. Cipriani A, Saunders K, Attenburrow MJ, Stefaniak J, Panchal P,
Stockton S, et al. A systematic review of calcium channel
antagonists in bipolar disorder and some considerations for their
future development. Mol Psychiatry. 2016;21:1324–32.
45. Biala G, Kruk-Slomka M, Jozwiak K. Influence of acute or
chronic calcium channel antagonists on the acquisition and con-
solidation of memory and nicotine-induced cognitive effects in
mice. Naunyn Schmiedebergs Arch Pharm. 2013;386:651–64.
46. Woodside BL, Borroni AM, Hammonds MD, Teyler TJ. NMDA
receptors and voltage-dependent calcium channels mediate dif-
ferent aspects of acquisition and retention of a spatial memory
task. Neurobiol Learn Mem. 2004;81:105–14.
47. Yarotskyy V, Gao G, Du L, Ganapathi SB, Peterson BZ, Elmslie
KS. Roscovitine binds to novel L-channel (CaV1.2) sites that
separately affect activation and inactivation. J Biol Chem.
2010;285:43–53.
48. Tomizawa K, Ohta J, Matsushita M, Moriwaki A, Li ST, Takei K,
et al. Cdk5/p35 regulates neurotransmitter release through phos-
phorylation and downregulation of P/Q-type voltage-dependent
calcium channel activity. J Neurosci. 2002;22:2590–7.
G. Chapman et al.
